Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: An open-label, randomised study

European Review for Medical and Pharmacological Sciences

Volumn 7, Issue 2, 2003, Pages 45-55

  Ederle, K ^a   Adolph, J ^b   Alschner, G ^b   Askar, B ^b   Asten, S ^b   Bachfischer, H ^b   Bamberg, R ^b   Bastlein S ^b   Baumann, E ^b   Becher, G ^b   Beck, E ^b   Bergmann, M ^b   Beuing, H ^b   Bezler, A ^b   Blum, H C ^b   Bock, A ^b   Boge K ^b   Botzen, U ^b   Brachmann, I ^b   Breitkopf, A ^b   Bruggen H ^b   Brunner, R ^b   Buchbender, H ^b   Bucher, M ^b   Burmeister, P ^b   Daelmann, E ^b   Dunzel M ^b   Duttler, S ^b   Eckhard, J G ^b   Ehl, W ^b   Eilers, A ^b   Felgner, U ^b   Fischer, J ^b   Focking, M ^b   Franz, L ^b   Gehrig, K P ^b   Ginko, T ^b   Glanz, R ^b   Gobel W ^b   Grasser M T ^b   Grimm, C M ^b   Grutzmann J C ^b   Gunsberg K ^b   Haberstumpf, H ^b   Hartung, H C ^b   Harzbecker, A ^b   Hehemann, K ^b   Hilsmann, U ^b   Jahn, M ^b   Jasch, B ^b   Jestel, L ^b   Jezek, M ^b   Kassner F ^b   Kehrwieder, A ^b   Kreiker, C ^b   Krezdorn, H G ^b   Krieg, U ^b   Kroemer, B ^b   Kroidl, R F ^b   Lock K ^b   Luther, R ^b   Maczek, P ^b   Maier Bosse, I ^b   Mauersberger, H ^b   Mayer, M ^b   Maykemper, B ^b   Mey, J ^b   Mikloweit, P ^b   Mittermeier, G ^b   Muller O ^b   Neugart, G ^b   Oertel, R ^b   Oldenburg, W ^b   Papsdorf, G ^b   Pfeifer, W ^b   Pfeuffer, H P ^b   Rabe, U ^b   Rastetter Gutmann, B ^b   Rebholz, G ^b   Redlich, R ^b   Scheffler, N K ^b   Schilling, W ^b   Schmidtmann, S ^b   Schmitt, M ^b   Schroder W ^b   Schroder Babo W ^b   Sim, T A ^b   Speier, U ^b   Steinhauser, U ^b   Stiller, D ^b   Stockle G ^b   Stutz, P ^b   Sumadiwiria, T ^b   Szasz I ^b   Talkner, F ^b   Thomas, J ^b   Uhde, C ^b   Vahlbruch, A ^b   Vehar, H ^b   more..

^a Klinik Lowenstein   (Germany)

^b NONE

Author keywords

Asthma; Autohaler ; Corticosteroid; HFA BDP; QVAR ; Vetolair

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID DERIVATIVE; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE; OVAR; PLACEBO; VENTOLAIR;

ADULT; AGED; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EXPIRATORY FLOW RATE; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; OPEN STUDY; POWDER INHALER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; THRUSH;

ADOLESCENT; ADULT; AEROSOL PROPELLANTS; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MIDDLE AGED; PARTICLE SIZE; PEAK EXPIRATORY FLOW RATE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0041308195     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Newman SP. Aerosol physiology, deposition, and metered dose inhalers. Allergy Proc 1991; 12: 42-45.
2. June DS, Schultz DW. Improved performance of CFC-free aerosol MDIs. J Aerosol Med 1995; 8: 91.
3. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346-1353.
4. Mitchell JP, Nagel MW, Archer AD. Size analysis of a pressurized metered dose inhaler-delivered suspension formulation by the API Aerosizer time-of-flight aerodynamic particle size analyzer. J Aerosol Med 1999; 12: 255-264.
5. Dolovich MB, Rhem R, Gerrard L, Coates G. Lung deposition of coarse CFC vs fine HFA pMDI aerosols of beclomethasone dipropionate (BDP) in asthma [abstract]. Am J Respir Crit Care Med 2000; 61: A33.
6. Donnell D, Anderson RN. Comparative particle size of inhaled corticosteroids. Poster presented at ACAAI 2001.
7. Asmus MJ, Liang J, Coowanitwong I, Hochhaus G. Respirable dose of fluticasone from a metered-dose inhaler (MDI) and two dry-powder inhalers (DPI). Am J Respir Crit Care Med 2001; 163: A444.
8. Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14: 197-208.
9. Conway JH, Walker P, Perkins G, Fleming JS, Holgate ST. Lung deposition characteristics of HFA-134a beclamethasone diproprionate delivered via an Autohaler. Eur Respir J 1999; 14 (Suppl. 30): 196s.
10. Leach CL. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999; 104: S250-252.
11. Newman SP, Pavia D, Clarke SW. Improving the bronchial deposition of pressurized aerosols. Chest 1981; 80: 909-914.
12. Jackson C, Lipworth B. Optimizing inhaled drug delivery in patients with asthma. Br J Gen Pract 1995; 45: 683-687.
13. Laube BL. In vitro measurements of aerosol dose and distribution: clinical relevance. J Aerosol Med 1996; 9 (Suppl. 1): S77-S92.
14. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215-1222.
15. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 1999; 115: 343-351.
16. Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir Med 2000; 94: 549-555.
17. Phillips GH. Structure activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84 (Suppl. A): 19-23.
18. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52 (Suppl. 39): 1-34.
19. Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 μg/day) versus HFA-fluticasone propionate (1000 μg/day) in patients with asthma. Respir Med 2001; 95: 212-220.
20. Fairfax AJ, Hall I, Spelman R. A randomised, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann Allergy Asthma Immunol 2001; 86: 575-582.
21. Reichel W, Dahl R, Ringdahl N, Zetterstron O, Van Den Elshout SJJ, Laitinen LA. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int J Clin Pract 2001; 55: 100-106.
22. Worth H, Muir JP, Pieter WR. Comparison of HFA-beclomethasone dipropionate Autohaler™ with budesonide Turbuhaler™ in asthma control. Respiration 2001; 68: 517-526.
23. Donnell D. Inhaled corticosteroid delivery systems: clinical role of a breath-actuated device. Eur Rev Med Pharmacol Sci 2001; 5: 7-16.
24. Nunn AJ, Gregg I. New regression equations for predicting peak expiratory flow in adults. Br Med J 1989; 298: 1068-1070.
25. Snell NJC. Assessing equivalence of inhaled products. J Pharm Pharmacol 1997; 49 (Suppl. 3): 55-60.
26. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104: S258-267.
27. Marshik PL, Larsen JS, Leach CL, et al. A novel breath actuated device (Autohaler) consistently actuates during the early phase of inspiration. J Aerosol Med 1995; 8: 187-195.
28. Demedts M, Cohen R, Hawkinson R. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int J Clin Pract 1999; 53: 331-338.
29. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med 2000; 94: 496-500.
30. Laviolette M, Prenner BM, Vincken W, Mol SJM. Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol. Eur Respir J 2001; 18 (Suppl. 33): 330s.
31. Fireman P, Prenner BM, Vinken W, et al. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 2001; 86: 557-565.
32. Juniper EF, Buist AS. Health-related quality of life in moderate asthma: 400 μg hydrofluoroalkane beclomethasone dipropionate vs 800 μg chlorofluorocarbon beclomethasone dipropionate. The Study Group. Chest 1999; 116: 1297-1303.
33. Juniper EF, Price DB, Stampone PA, et al. Clinically important improvements in asthma-specific quality of life but no difference in conventional clinical indices in patients changed from conventional BDP to approximately half the dose of extrafine BDP. Chest 2002; 121: 1824-1832.
34. Sullivan S, Elixhauser A, Buist AS, et al. National Asthma Education and Prevention Program Working Group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996; 154: 584-595.
35. Ayres JG, Frost C, Holmes WF, Venables KM, Ward SM. Twelve week, non-interventional, post-marketing surveillance study to compare the safety of HFA-134a beclomethasone dipropionate (BDP) with CFC-BDP inhalers. Eur Respir J 2000; 16 (Suppl. 31): 281S.